Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. Co. has built its proprietary FUSION System discovery platform to develop a pipeline of covalent small molecule product candidates. Co.'s product candidate, BMF-219, is designed to be an orally bioavailable, selective irreversible covalent inhibitor of menin, a scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. The BMEA stock yearly return is shown above.
The yearly return on the BMEA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BMEA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|